The role of pharmacogenetics in the metabolism of antiepileptic drugs: Pharmacokinetic and therapeutic implications

Clinical Pharmacokinetics

Volumn 46, Issue 4, 2007, Pages 271-279

  Klotz, Ulrich ^a,b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ARYLAMINE ACETYLTRANSFERASE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLONAZEPAM; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DEBRISOQUINE; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; ISONIAZID; LAMOTRIGINE; MEPHENYTOIN; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; SPARTEINE; SULFAPYRIDINE; SULFONAMIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ALLELE; AREA UNDER THE CURVE; ASIAN; CAUCASIAN; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; EPILEPSY; ETHNIC DIFFERENCE; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; GINGIVA HYPERPLASIA; HUMAN; IN VITRO STUDY; LIVER INJURY; LIVER TOXICITY; NONHUMAN; OXIDATIVE STRESS; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN MANIFESTATION; VOMITING;

ALLELES; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 ENZYME SYSTEM; DRUG MONITORING; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION; HUMANS; MUTATION; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PRACTICE GUIDELINES;

EID: 33947729635     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200746040-00001     Document Type: Review

References (64)

1. Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Invest Drugs 2006; 15: 637-47
2. Neels HM, Sierens AC, Naelaerts K, et al. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab 2004; 42: 1228-55
3. Johannessen SI. Can pharmacokinetic variability be controlled for the patient's benefit? The place of TDM for new AEDs. Ther Drug Monit 2005; 27: 710-3
4. Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 2001; 15: 897-918
5. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211-21
6. Williams JA, Johnson K, Paulauskis J, et al. So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics. J Clin Pharmacol 2006; 46: 258-64
7. Pirazzoli A, Recchia G. Pharmacogenetics and pharmacogenomics: are they still promising? Pharmacol Res 2004; 49: 357-61
8. Kalow W. Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogen J 2006; 6: 162-5
9. Vogel F. Moderne Probleme der Humangenetik. Ergeb Inn Med Kinderheilkd 1959; 12: 52-125
10. Lewis LD. Editors' view: personalized drug therapy; the genome, the chip and the physician. Br J Clin Pharmacol 2005; 60: 1-4
11. Bonicke R, Lisboa BP. Über die Erbbedingtheit der intraindividuellen Konstanz der Isoniazidausscheidung beim Menschen. Naturwissenschaften 1957; 44: 314-20
12. Fischer C, Klotz U. High-performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites: its application for pharmacokinetic studies with salicylazosulfapyridine in man. J Chromatogr Biomed Appl 1979; 162: 237-43
13. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. TRENDs Pharmacol Sci 2004; 25: 193-200
14. Alexanderson B, Evans DA, Sjöqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J 1969; 4: 764-8
15. Eichelbaum M. Ein neuentdeckter Defekt im Arzneimittelstoffwechsel des Menschen: die fehlende N-Oxidation des Spartein [thesis]. Bonn: Universität Bonn, 1975
16. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584-6
17. Cytochrome P450 drug-interaction table [online]. Available from URL: http://medicine.iupui.edu/flockhart/table.htm [Accessed 2007 Feb 27]
18. Andersson T, Flockhart DA, Goldstein DB, et al. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther 2005; 78: 559-81
19. Küpfer A, Desmond P, Patwardhan R, et al. Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clin Pharmacol Ther 1984; 35: 33-9
20. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochromes P450 (CYP)2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-209
21. Xie H-G, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenet 1999; 9: 539-49
22. Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Disp 2005; 33: 1567-75
23. Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77: 1-16
24. Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus. Eur J Neurol 2006; 13: 445-50
25. Walker DM, Teach SJ. Update on the acute management of status epilepticus in children. Curr Opin Pediatr 2006; 18: 239-44
26. Bertilsson L, Baillie TA, Reviriego J. Factor influencing the metabolism of diazepam. Pharmac Ther 1990; 45: 85-91
27. Andersson T, Miners JO, Veronese ME, et al. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994; 38: 131-7
28. Bertilsson L, Henthorn T, Sanz TK, et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1989; 45: 348-55
29. Desta Z, Zhao X, Shin J-G, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-58
30. Inomata S, Nagashima A, Itagaki F, et al. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther 2005; 78: 647-55
31. Mamiya K, Hadama A, Yukawa E, et al. CYP2C19 polymorphism effect on phenobarbitone: pharmacokinetics in Japanese patients with epilepsy. Analysis by population pharmacokinetics. Eur J Clin Pharmacol 2000; 55: 821-5
32. Mamiya k, Ieiri I, Shimamoto J, et al. The effects of polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 1998; 39: 1317-23
33. Bajpai M, Roskos LK, Shen DD, et al. Roles of cytochrome P450 2C9 and cytochrome P450 2C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Disp 1996; 24: 1401-3
34. Kidd RS, Curry TB, Gallagher S, et al. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenet 2001; 11: 803-8
35. Aynacioglu AS, Brockmöller J, Bayer S, et al. Frequency of cytochrome P450 CYP2 C19 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48: 409-15
36. Rosemary J, Surendiran A, Rajan S, et al. Influence of the CYP2C9 and CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India. Indian J Med Res 2006; 123: 665-70
37. Tate SK, Depondt C, Sisodiya SM, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. PNAS 2005; 102: 5507-12
38. Hung C-C, Lin C-J, Chen C-C, et al. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther Drug Monit 2004; 26: 534-40
39. Lee AY, Kim MJ, Chey WY, et al. Genetic polymorphism of cytochrome P450 2C9 in 70 diphenylhydantoin-induced cutaneous adverse drug reactions. Eur J Clin Pharmacol 2004; 60: 155-9
40. Soga Y, Nishimura F, Ohtsuka Y, et al. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci 2004; 74: 827-34
41. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2001; 16: 660-94
42. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695-714
43. Rettie AE, Rettenmeier AW, Howald WN, et al. Cytochrome P450-catalyzed formation of Δ′4-VPA, a toxic metabolite of valproic acid. Science 1987; 235: 890-2
44. Cotariu D, Zaidman JL. Valproic acid and the liver. Clin Chem 1988; 34: 890-7
45. Davis R, Peters DH, McTravish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47: 332-72
46. Sadeque AJM, Fisher MB, Korzekwa KR, et al. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 1999; 283: 698-703
47. Ho PC, Abbott FS, Zanger UM, et al. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogen J 2003; 3: 335-42
48. Tong V, Teng XW, Chang TK, et al. Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. Toxicol Sci 2005; 86: 427-35
49. Tomson T, Tybring G, Bertilsson L. Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. Clin Pharmacol Ther 1983; 33: 58-65
50. Nakajima Y, Saito Y, Shiseki K, et al. Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur J Clin Pharmacol 2005; 61: 25-34
51. Hung S-I, Chung W-H, Jee S-H, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genom 2006; 16: 297-306
52. Depondt C. The potential of pharmacogenetics in the treatment of epilepsy. Eur J Paediatr Neurol 2006; 10: 57-65
53. Ferraro T, Dlugos DJ, Buono RJ. Challenges and opportunities in the application of pharmacogenetics to antileptic drug therapy. Pharmacogenom 2006; 7: 89-103
54. Szoeke C, Newton M, Wood JM, et al. Update on pharmacogenetics in epilepsy: a brief review. Lancet Neurol 2006; 5: 189-96
55. Gardiner SJ, Begg EJ. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genom 2005; 15: 365-9
56. Bialer M. The pharmacokinetics and interactions of new antiepileptic drugs. Ther Drug Monit 2005; 27: 722-6
57. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006; 61: 246-55
58. Deckers CLP, Knoester PD, de Haan GJ, et al. Selection criteria for the clinical use of the newer antiepileptic drugs. CNS Drugs 2003; 17: 405-21
59. Hitiris N, Brodie MJ. Modern antiepileptic drugs: guidelines and beyond. Curr Opin Neurol 2006; 19: 175-80
60. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003; 25: 347-63
61. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 2006; 45: 1061-75
62. Kirchheiner J, Fuhr U, Brockmöller J. pharmacogenetics-based therapeutic recommendations: ready for clinical practice? Nature Rev Drug Discov 2005; 4: 639-47
63. Philipps KA, van Bebber SL. Measuring the value of pharmacogenomics. Nat Rev Drug Discov 2005; 4: 500-9
64. Hamacher M, Apweiler R, Arnold G, et al. HUPO brain proteome project: summary of the pilot phase and introduction of a comprehensive data reprocessing strategy. Proteomics 2006; 6: 4890-8